MD, University of Chile Medical School
Residency, Internal Medicine
The Brooklyn Hospital
Residency, Internal Medicine
Brooklyn Hospital-Caledonian Hosp.
Downstate Medical Center
American Board of Internal Medicine
Uribarri J, Buquing J, Oh MS. Acid-base balance in chronic peritoneal dialysis patients. Kidney Int 1995 Jan; 47(1): 269-273.
Uribarri J. Acid production in chronic hemodialysis patients. J Am Soc Nephrol 1998 Jan; 9(1): 114-120.
Uribarri J, Oh MS, Carroll HJ. D-lactic acidosis: a review of clinical presentation, biochemical features and pathophysiologic mechanisms. Medicine 1998 Mar; 77(2): 73-82.
Uribarri J, Levin NW, Delmez J, Depner TA, Ornt D, Owen W, Yan G. Association of acidosis and nutritional parameters in hemodialysis patients. Am J Kidney Dis 1999 Sep; 34(3): 493-499.
Uribarri J. Doqi guidelines for nutrition in long-term peritoneal dialysis patients: a dissenting view. Am J Kidney Dis 2001 Jun; 37(8): 1313-1318.
Sedlacek M, Teodorescu V, Falk A, Vassalotti JA, Uribarri J. Hemodialysis access placement with preoperative noninvasive vascular mapping: comparison between patients with and without diabetes. Am J Kidney Dis 2001 Sep; 38(3): 560-564.
Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, Baliga S, Vassalotti JA, Vlassara H. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kid Dis 2003 Sep; 42(3): 532-538.
Uribarri J, Peppa M, Goldberg T, Cai W, Lu M, He C, Vlassara H. Restriction of dietary glycotoxins markedly reduces elevated advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14: 728-731.
Caplin N, Sedlacek M, Teodorescu V, Falk A, Uribarri J. Venous access: women are equal. Am J Kidney Dis 2003 Feb; 41(2): 429-432.
Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004 Apr; 43(4): 690-695.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Uribarri during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.